Zydus receives FDA final approval for Diroximel fumarate delayed-release capsules, 231 mg
Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis
Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance
This partnership has led to a 10% boost in delivery speed
Moraine will serve as OTSAW’s exclusive distributor in Japan, deploying the Camello+ autonomous mobile robot and TransCar autonomous guided vehicle to support hospital logistics
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
Subscribe To Our Newsletter & Stay Updated